Grant Recipient/Supplier	Reporting Period - Cal Description	Commencement Date	Completion Date	Value	Confidentiality	Record ID
	Capacity building support to the Breast Cancer Trials (BCT) to develop	commencement Date	completion Date	(GST incl)	provisions Y/N	Record ID
Australia and New Zealand Breast Cancer Trials Group	industry independent cancer clinical trial protocols to the stage of application for grant funding Supporting people with cancer Grant initiative - Optimising the	29/06/2018	01/03/2022	\$1,919,039.10	N	CA 1718 172
Austin Health	engagement of Culturally and Linguistically Diverse cancer patients and their families with supportive care designed to improve wellbeing.	1/05/2018	30/04/2022	\$132,000	Ν	CA-G1718-35
Australian Leukaemia and Lymphoma Group	Capacity building support to the Australasian Leukaemia and Lymphoma Group (ALLG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	29/06/2018	01/03/2022	\$1,925,000.00	Ν	CA 1718 170
Australian National University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: AUTO-CHECK study: Molecular determinants of autoimmunity and immune related adverse events in advanced cancer patients treated with immune checkpoint inhibitors. APPID: 1130330-COOK	25/04/2017	30/04/2022	\$574,009.00	Ν	CA-G1516/74
Canberra Hospital Foundation	Supporting people with cancer Grant initiative - Pathways to wellbeing for Aboriginal and Torres Strait Islander people with cancer in the ACT and surrounding regions	30/06/2021	30/06/2024	\$132,000	Ν	GA176982
Cancer Council NSW	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Hide and seek with hereditary cancer: Improving detection of colorectal cancer patients with a high risk of Lynch syndrome. APPID: 1123924- TAYLOR	30/06/2017	31/12/2022	\$579,140.00	Ν	CA-G1516/70
Central Adelaide Local Health Network	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: A new gene modification strategy for generating optimised CAR-T cells for therapy of glioblastoma. APPID: 2003828-BROWN	01/10/2021	30/12/2024	\$600,000.00	Ν	2003828
Central Adelaide Local Health Network	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Predicting and improving anti-tumour responses to immunotherapy in advanced cancer patients. APPID: 1186306-EBERT	01/06/2020	31/08/2023	\$560,142.00	Ν	1186306
Circular Head Aboriginal Corporation	Supporting people with cancer Grant initiative- Supporting Aboriginal people affected by cancer in a remote Tasmanian community: Developing the cultural and clinical pathway. (Healing journeys)	01/07/2021	01/06/2024	\$127,600	N	GA176999
Derbarl Yerrigan Health Services Aboriginal Corporation	Supporting people with cancer Grant initiative - Wangkiny moorditch nyin (good talking circle/sitting down)(Yarning both ways)	1/07/2021	1/06/2024	\$132,000	Ν	GA177002
Flinders University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Increasing resilience and reducing smoking for lower socio-economic groups. APPID: 1182598-WARD	01/06/2020	26/01/2024	\$553,820.00	Ν	1182598
Flinders University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Personalising treatment and surveillance for colorectal cancer: prognostication with the circulating tumour-derived methylated DNA markers BCAT1 and IKZF1 AppID: 1161720 - SYMONDS	01/06/2019	31/08/2022	\$553,196.00	Ν	CA 1819 103
Flinders University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: Targeting CDK9 in lethal prostate cancer. APPID: 2001432-SELTH	30/06/2021	29/09/2024	\$459,811.00	Ν	2001432
Griffith University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Circulating Tumour Cells: Clinical Application in Head and Neck Cancers. APPID: 1145657-PUNYADEERA	29/06/2018	28/09/2022	\$599,756.00	Ν	CA-G1718-11
La Trobe University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: A multistage multicentre international randomised trial of Conventional care Or Radioablation (stereotactic body radiotherapy) for Extra-cranial oligometastatic disease in lung, breast and prostate cancer (CORE). APPID: 1104569-Foroudi	28/06/2016	31/03/2022	\$430,563.00	Ν	CA-G1516/32
La Trobe University	Priority-driven Collaborative Cancer Research Scheme international (PdCCRSi) 2018: Tackling Breast Cancer Heterogeneity for the Complete Eradication of Metastases. APPID: CCR19606878-MERINO	15/05/2019	15/08/2022	\$300,000.00	Ν	CCR19606878
Maquairie University (Formely University of New South Wales)	Supporting people with cancer Grant initiative - Co-designing patient engagement strategies to enhance safety in cancer services for culturally and linguistically diverse (CALD) patients.	01/06/2019	30/04/2023	\$119,660.25	Ν	CA18/19 01
Monash University	Capacity building support to the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	29/06/2018	01/03/2022	\$1,750,000.00	Ν	CA 1718 173
Monash University	Capacity building support to the Melanoma and Skin Cancer Trials (MASC; formerly ANZMTG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	29/06/2018	01/03/2022	\$1,750,000.00	Ν	CA 1718 175
Monash University	Investing in medical Research - fighting childhood cancer: LGG Avastin study	27/10/2017	31/08/2023	\$506,419	Ν	CA 1718 044
Monash University	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019 international: Checkpoint receptors expressed by dendritic cells- do they play a role in immunotherapies? APPID: 20-0300-O'KEEFE	01/02/2020	01/05/2023	\$241,027.00	N	20-0300
Monash University	Supporting people with cancer Grant initiative - Integrated Management of Post Remission Leukaemia to Optimise longevity and Enhance Quality of Life (IMPROVE)	01/04/2019	30/05/2023	\$120,000	N	CA1819126PO111 7
Monash University (Formely Melanoma and Skin Cancer Trials Limited )	Supporting people with cancer Grant initiative Improving Melanoma and Skin Cancer awareness in regional and rural Australia	1/04/2019	30/05/2022	\$132,000	Ν	CA1819126PO111 9
Mujaay Ganma Foundation Aboriginal Corporation	Supporting people with cancer Grant initiative- Country and Culture - Caring and Healing project.	01/07/2021	01/06/2024	\$125,697	N	GA176995
North Metropolitan Health Service, WA	Supporting people with cancer Grant initiative - Adolescent and Young Adult (AYA) Life Now Group Exercise Program	30/06/2017	30/09/2022	\$112,462	N	CA-G1617/80
Queensland University of Technology	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Development of a translational bioengineered microenvironment model to advance pre-clinical acute myeloid leukaemia research AppID: 1159637 BRAY	30/06/2019	29/09/2022	\$133,017.00	Ν	CA 1819 146
Queensland University of Technology	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Humanized rat models - the next frontier in pre-clinical osteosarcoma research APPID: 1181919-McGOVERN	01/01/2021	31/03/2023	\$131,710.00	Ν	1181919
Swinburne University of Technology	Supporting people with cancer Grant initiative - Australian Carers Talk	01/04/2019	30/05/2022	\$120,000	N	CA1819126PO111 6
Queensland Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: The harms and benefits of sun exposure: striking the right balance. APPID: 2000511-GORDON	14/06/2021	13/09/2024	\$528,984.00	Ν	2000511
University of Newcastle	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Obesity epidemic fuelling the surge of endometrial cancers: Elucidating the role and targeting of molecular signals involved in fat and endometrial cancer cross-talk. APPID: 1187542-TANWAR	31/03/2020	28/05/2023	\$600,000.00	Ν	1187542

	Reporting Period - Cale					
University of Sydney	Capacity building support to the Australasian Leukaemia and Lymphoma Group (AGITG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	29/06/2018	01/03/2022	\$1,750,000.00	N	CA 1718 169
University of Sydney	Capacity building support to the Thoracic Oncology Group of Australasia (TOGA; formerly ALTG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	29/06/2018	01/03/2022	\$1,750,000.00	Ν	CA 1718 171
University of Sydney	Capacity building support to the Australia New Zealand Gynaecological Oncology Group (ANZGOG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	29/06/2018	01/03/2022	\$1,750,000.00	Ν	CA 1718 174
University of Sydney	Capacity building support to the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	29/06/2018	01/03/2022	\$1,750,000.00	Ν	CA 1718 176
University of Sydney	Capacity building support to the Cooperative Trials Group for Neuro- Oncology (COGNO) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	29/06/2018	01/03/2022	\$1,750,000.00	Ν	CA 1718 178
University of Sydney	Capacity building support to the Psycho-oncology Co-operative Research Group (PoCoG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	29/06/2018	01/03/2022	\$1,727,995.00	N	CA 1718 179
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: P3BEP Trial: Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours: An Australian-Led, International Randomised Trial. AppID: 1159837-GRIMISON	30/06/2019	29/09/2022	\$600,000.00	Ν	CA 1819 116
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Improving tumour targeting and delineation in lung cancer radiotherapy AppID: 1161748-O'BRIEN	30/06/2019	29/09/2023	\$600,000.00	Ν	CA 1819 182
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: The ECHO trial: Exercise during Chemotherapy for Ovarian cancer AppID: 1158566-HAYES	14/05/2019	13/08/2022	\$597,443.00	Ν	CA 1819 122
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Personalised targeted therapy for adolescent and young adult medulloblastoma patients AppID: 1165910-HOVEY	30/06/2019	29/09/2022	\$167,168.50	Ν	CA 1819 115
Walter and Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: Designing personalised treatment strategies for KEAP1-mutant lung cancer. APPID: 2003127-Best	30/06/2021	29/09/2023	\$200,000.00	Ν	2003127
Trans Tasman Radiation Oncology Group Limited	Capacity building support to the Trans Tasman Radiation Oncology Group (TROG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	29/06/2018	01/03/2022	\$1,925,000.00	Ν	CA 1718 180
Trans Tasman Radiation Oncology Group Limited	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Novel Integration of New prostate radiation schedules with adjuvant Androgen deprivation (NINJA) AppID: 1158455-MARTIN	30/06/2019	29/09/2022	\$600,000.00	Ν	CA 1819 112
University of Adelaide	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2012: A pharmacodynamic study of the heat shock protein 90 (Hsp90) inhibitor, AUY922, in high-risk, localised prostate cancer. APPID: 1050880-BUTLER	01/05/2013	31/03/2022	\$360,977.00	Ν	CA-A 1213/28
University of Melbourne	Capacity building support to the Australia and New Zealand Sarcoma Association (ANZSA; formerly ASSG) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	29/06/2018	01/03/2022	\$1,750,000.00	Ν	CA 1718 177
University of Melbourne	Capacity building support to the Primary Care Collaborative Cancer Clinical Trials Group (PC4) to develop industry independent cancer clinical trial protocols to the stage of application for grant funding	29/06/2018	01/03/2022	\$1,750,000.00	Ν	CA 1718 181
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019 international: Checkpoint receptors expressed by dendritic cells- do they play a role in immunotherapies? APPID: 663175-DAWSON	01/01/2021	31/03/2024	\$670,500.00	Ν	663175
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: SCRIPT: an RCT of genomic-based stratified colorectal cancer screening in primary care. APPID: 1183338-EMERY	30/06/2020	29/09/2023	\$551,184.00	Ν	118338
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Integrative approaches to identifying the causes of familial breast cancer. APPID: 1188547-CAMPBELL	27/04/2020	26/07/2023	\$547,825.00	Ν	1188547
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: The Preclinical Validation of Radio-labelled Girentuximab as a Theranostic Agent in Metastatic Colorectal Cancer. APPID: 1184859-HOLLANDE	23/03/2020	22/06/2023	\$506,210.00	Ν	1184859
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: A combined immuno-molecular biomarker for early breast disease. APPID: 2002944-GORRINGE	14/06/2021	13/09/2024	\$498,695.00	Ν	2002944
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: Augmenting CXCR3 ligand production to enhance the trafficking of T cells in solid cancers. APPID: 2001335-BEAVIS	01/06/2021	30/08/2024	\$497,672.00	Ν	2001335
University of Melbourne	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: SCORE: Shared care of Colorectal cancer survivors – A randomised controlled trial of hospital-based follow up versus shared hospital / general practice follow up for survivors of colorectal cancer (CRC) AppID: 1158397-JEFFORD	01/04/2019	30/11/2022	\$479,375.00	Ν	CA 1819 107
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Functional precision medicine for aggressive childhood cancers. APPID: 1185313-KAVALLARIS	01/10/2020	30/12/2023	\$596,955.00	Ν	1185313
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Microtubule deregulation in lung cancer and therapeutic strategies APPID: 1141485-KAVALLARIS	29/03/2018	31/03/2022	\$592,694.00	Ν	CA-G1718-14
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Decoding the Dark Matter of the High-Risk Paediatric Cancer Genome AppID: 1165556-COWLEY	07/05/2019	06/08/2022	\$377,048.00	Ν	CA 1819 104
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Functional precision medicine for aggressive childhood cancers. APPID: 1188234-HABER	01/01/2021	31/03/2024	\$347,705.00	Ν	1188234
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting the NAD pathway as a new therapeutic strategy for high-risk leukaemia in children AppID: 1164865-HENDERSON	20/05/2019	19/08/2022	\$321,045.00	Ν	CA 1819 110
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Application of gene-silencing nanodrugs to inhibit medulloblastoma growth. APPID: 1184840-McCARROLL	26/02/2020	25/05/2023	\$298,554.00	Ν	1184840

	Reporting Period - Cal	enual fear - 202	T			
University of New South Wales	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting Polo-like kinase 1 as a novel therapeutic opportunity for Diffuse Intrinsic Pontine Gliomas AppID: 1165708-ZIEGLER	28/05/2019	27/05/2022	\$278,281.00	Ν	CA 1819 109
University of New South Wales	Supporting people with cancer Grant initiative - BRIDGES-4AYA: Returning to Employment and Study for Adolescents and Young Adults with cancer	30/06/2021	30/06/2024	\$120,000	Ν	GA176979
University of Queensland	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: Long-read genetic and epigenetic profiling in lung cancer for precision medicine. APPID: 2003170-FAULKNER	30/06/2021	29/09/2024	\$567,596.00	Ν	2003170
University of Queensland	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Streamlining lung cancer diagnosis through genomic testing of cytology smears APPID: 1147067-FIELDING	30/06/2018	30/09/2022	\$400,000.00	Ν	CA-G1718-32
University of Queensland	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Exploiting CDK4/6 inhibition to treat medulloblastoma AppID: 1165777- WAINWRIGHT	30/06/2019	29/09/2022	\$196,206.00	Ν	CA 1819 113
University of Queensland (Former Menzies School of Health Research)	Supporting people with cancer Grant initiative - Optimising equitable access to cancer research participation for Aboriginal and Torres Strait Islander people: Development of culturally-responsive resources to guide informed decision-making	30/06/2021	30/06/2024	\$119,150.00	Ν	GA176978
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019:Immuno-metabolic biomarkers to predict treatment response in metastatic prostate cancer APPID: 1188642-HORVATH	01/01/2021	31/03/2024	\$600,000.00	Ν	1188642
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: ICON9: A phase 3 randomised trial of cediranib and olaparib maintenance in patients with relapsed platinum sensitive ovarian cancer. APPID: 1100619-MILESHKIN	15/04/2016	31/06/2022	\$600,000.00	Ν	CA-G1516/34
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: The PEARL trial: Palliative care Early in Advanced Lung cancers. APPID: 1101882-MILESHKIN	18/04/2016	31/03/2022	\$598,099.00	Ν	CA-G1516/37
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Life and Health After Childhood Cancer: a national data linkage cohort study. APPID: 1187545-NASSAR	01/06/2020	31/08/2023	\$569,900.00	Ν	1187545
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Remove the Mask: Reducing Anxiety and Distress for Head and Neck Cancer Radiotherapy Patients. APPID: 1180776-KEALL	30/06/2020	29/09/2023	\$568,445.00	Ν	1180776
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2015: Phase II randomised placebo-controlled, double blind, multisite study of acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive HGG requiring treatment with dexamethasone – The ACED trial. APPID: 1098932-AGAR	01/04/2016	30/03/2022	\$524,365.00	Ν	CA-G1516/24
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: ASCOLT: ASpirin for Dukes C and high risk B COLorecTal cancer. An International, Multi-centre, Double Blind, Randomised Trial. APPID: 1182824-SEGELOV	13/05/2020	12/08/2023	\$465,000.00	Ν	1182824
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS)2018: Therapeutic targeting of a novel self-renewal signalling in leukaemia stem cells AppID: 1165516-WANG	30/06/2019	31/03/2023	\$300,000.00	Ν	CA 1819 111
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Empowering the clinician-patient-carer trio: RCT of novel online education modules to facilitate effective family carer involvement in oncology. APPID: 1146383-JURASKOVA	19/03/2018	18/03/2023	\$296,601.00	Ν	CA-G1718-05
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma: the CODEL trial APPID: 1130594-HOVEY	30/06/2017	30/09/2022	\$221,534.04	N	CA-G1516/67
University of Sydney	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2016: The SPAR Trial: a randomised placebo-controlled phase 2 trial of simvastatin with preoperative chemoradiation for rectal cancer. APPID: 1125958-ACKLAND	30/06/2017	31/03/2023	\$148,857.00	Ν	CA-G1516/85
University of Sydney	Supporting people with cancer Grant initiative -Aboriginal people with cancer to access evidence based care: developing a manual and training package in use for workers in primary care to support cancer care.	01/06/2019	30/05/2022	\$120,000	Ν	CA 1819 181
University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Mixed radiotherapy fractionation: modulating tumour microenvironment to stimulate and enhance immunotherapy AppID: 1163065-EBERT	01/05/2019	30/07/2023	\$597,521.00	Ν	CA 1819 123
University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2017: Measuring breast density in younger women to inform primary prevention and early detection of breast cancer. APPID: 1147677-STONE	08/03/2018	31/03/2022	\$592,636.00	Ν	CA-G1718-12
University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019 international: Improving anti-cancer therapy by stromal remodelling. APPID: 21-057-GANSS	01/03/2021	01/12/2024	\$214,398.53	Ν	21-0257
University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: Reprogramming the tumour microenvironment to improve immunotherapy. APPID: 2002303-HE	30/06/2021	29/09/2023	\$200,000.00	Ν	2002303
University of Western Australia	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2019: Intraoperative immunotherapy to prevent relapse in soft tissue sarcoma. APPID: 1184331-LESTERHUIS	01/04/2020	30/06/2022	\$197,525.00	Ν	1184331
Walter and Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting BCL-2 in estrogen receptor positive breast cancer AppID: 1165878-LINDEMAN	29/04/2019	28/07/2022	\$599,562.00	Ν	CA 1819 117
Walter and Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Designing Chimeric Antigen Receptor T cells for Diffuse Intrinsic Pontine Glioma AppID: 1164657-JENKINS	06/05/2019	05/08/2022	\$592,388.00	Ν	CA 1819 137
Walter and Eliza Hall Institute of Medical Research	Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2018: Targeting multidrug resistance protein 1 (MDR1) enhances the efficacy of Smac-mimetic-based therapy in Acute Myeloid Leukaemia AppID: 1162023-BRUMATTI	01/06/2019	31/08/2022	\$361,023.00	Ν	CA 1819 118
Waminda – South Coast Women's Health and Welfare Aboriginal Corporation	Supporting people with cancer Grant initiative- Waminda - Linking Shoalhaven's Cancer Care Services project.	1/07/2021	1/06/2024	\$132,000	Ν	PO554

Western Sydney University	Supporting people with cancer Grant initiative - Supporting the transition from hospital cancer treatment to wellness for women from Chinese, Vietnamese and Arabic backgrounds: a tailored stepped supportive care program	30/06/2021	30/06/2024	\$118,823.00	Ν	GA176989
---------------------------	--	------------	------------	--------------	---	----------